Resumen de: WO2021198157A1

The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).

Resumen de: CN114452385A

The invention discloses a coordination polymer nano-material with a photodynamic combined hunger treatment function as well as a preparation method and application of the coordination polymer nano-material. The coordination polymer nano-material comprises a carrier and an enzyme, the enzyme is loaded in the carrier, and the enzyme is glucose oxidase or mimic enzyme with activity similar to that of the glucose oxidase; the carrier is a 1, 2, 4-triazole copper (I) complex. GOx in the coordination polymer nanometer material can be specifically released in tumor cells, glucose in the tumor cells can be catalyzed to be oxidized, glucose and oxygen in the tumor cells can be consumed, the acidity level, the hypoxia level and the hydrogen peroxide level are improved, and therefore energy supply of the tumor cells is blocked, and hunger treatment is achieved. Meanwhile, hydrogen peroxide generated in hunger treatment can be used as a raw material for photodynamic reaction of the 1, 2, 4-triazole copper (I) complex, the I-type photodynamic treatment effect is enhanced, and finally efficient photodynamic combined hunger treatment is achieved.

Resumen de: CN115381793A

本发明提供了一种白蛋白负载阿苯达唑纳米药及其制备方法，属于生物纳米合成技术领域，其通过下述步骤得到：第一步将白蛋白、胰凝乳蛋白酶和弹性蛋白酶加入水中得到第一溶液；第二步，将阿苯达唑溶解于有机溶剂得到第二溶液，第三步将第一溶液与第二溶液充分混合；第四步和第五步进行去溶剂化交联，第六步先将第三步所得到的阿苯达唑纳米药进行透析纯化，第七步，将纯化后产物进一步加热固化然后冷却冻干获得纳米级阿苯达唑。本发明显著提高了阿苯达唑药物的溶解度和溶出速度，明显改善阿苯达唑生物利用度，有效地发挥阿苯达唑抗组织器官寄生虫的治疗作用。

Resumen de: CN115381770A

本发明属于医药技术领域，公开了一种同时递送两亲活性物质的海藻酸钙微凝胶及其制备方法与应用。本发明将疏水性的RES包裹进SNP制成R‑SNPs，提高RES溶解性与稳定性，进一步将R‑SNPs与亲水性的OPC共同裹入海藻酸钙微凝胶的方式实现两活性物质的靶向递送，不仅释药性好也可规避纳米粒子可能会产生的纳米毒性。所构建微凝胶为活性物质的靶向递送提供了一个新方向，为缓解溃疡性结肠炎开拓了新的前景。

Resumen de: CN115381947A

本发明提供了一种封装光敏剂的紫外交联桃胶多糖纳米球、制备方法及其应用，该制备方法为：将1重量份的水解桃胶多糖、2‑5重量份的肉桂酸、0.1‑1重量份4‑二甲氨基吡啶、0.5‑5重量份的N,N‑二环己基碳二亚胺于氮气氛围下溶于无水的N,N‑二甲基甲酰胺中，在室温下反应24‑48小时后，加入冰乙醇沉淀、洗涤3次，于60度烘箱中干燥至恒重，得到两亲性桃胶多糖‑肉桂酸共聚物；将所述两亲性桃胶多糖‑肉桂酸共聚物溶于有机溶剂中，当完全溶解后缓慢滴入相当于有机溶剂体积4‑9倍的水，然后透析8‑24小时，即可得到封装光敏剂桃胶多糖‑肉桂酸纳米球；最后将得到的封装光敏剂桃胶多糖‑肉桂酸纳米球在紫外光下光照0.5‑2小时，得到封装光敏剂的紫外交联稳定的桃胶多糖纳米球。

Resumen de: CN115381880A

本发明涉及生物医学技术领域，具体公开了一种融合纳米囊泡及其制备方法与应用。本发明的融合纳米囊泡包括间充质干细胞囊泡和植物外泌体融合而成的膜结构。本发明首次将植物来源的外泌体与人来源的间充质干细胞囊泡进行膜融合制备融合纳米囊泡，本发明的融合纳米囊泡具有很好的靶向性和生物相容性，该融合纳米囊泡具有抗炎抗氧化作用，并且具有免疫调节功能，能有效治疗特异性皮炎和银屑病，为制备用于治疗自身免疫病特别是特异性皮炎和银屑病的药物提供了一种新来源。

Resumen de: CN115381794A

本发明属于医药技术领域，公开了硼替佐米与青蒿琥酯的药物组合物、方法以及应用，乙醇注入法制备得到的青蒿琥酯‑硼替佐米脂质体，用于多发性骨髓瘤治疗。本发明进行细胞实验，在细胞水平验证青蒿琥酯‑硼替佐米脂质体对U266骨髓瘤细胞株的增殖抑制作用。实现青蒿琥酯‑硼替佐米脂质体有效的抗肿瘤作用，使用过程中安全、高效，为临床肿瘤化疗提供新的思路。

Resumen de: CN115381940A

本发明公开了一种靶向肿瘤放疗增敏剂及其制备方法，属于肿瘤治疗领域。本发明的靶向肿瘤放疗增敏剂为装载锰羰基(MnCO)的外泌体纳米囊泡(MMV)，其制备方法包括(1)培养肿瘤细胞；(2)提取肿瘤细胞的外泌体；(3)通过电转将MnCO转到外泌体中，得到装载MnCO的肿瘤来源外泌体纳米囊泡。本发明安全有效，为肿瘤治疗提供了新的方法或手段，并为肿瘤放射增敏治疗提供了一种简单可行的干预方法，具有良好的开发和应用前景。

Resumen de: WO2022245144A1

The present invention relates to: a method for production of cell-derived nanovesicles, the method comprising a step of lysing and dispersing cells under a high-pressure condition; and nanovesicles produced by the method. The method can produce cell-derived nanovesicles in uniform sizes and allows for mass production, compared to conventional methods, and thus can be advantageously used in the medical and pharmaceutical fields.

Resumen de: WO2022244680A1

The purpose of the present invention is to provide a contrast medium using a paramagnetic metal that accumulates at an abnormal protein deposition or aggregation site in the brain. Magnetic nanoparticles for image diagnosis which comprise magnetic iron oxide particles, gold fine particles supported on the surface of the magnetic iron oxide particles, a polymer chain attached to the gold fine particles and a molecule directing for a neurodegenerative disease-related protein and attached to at least a part of the polymer chain, and which are to be administered transnasally. These magnetic nanoparticles for image diagnosis are useful as an active ingredient of a contrast medium that accumulates at an abnormal protein deposition or aggregation site in the brain.

Resumen de: WO2022241513A1

The present application relates to metal-organic framework (MOF) encapsulation of lipid-nucleic acid formulations. The present application discloses methods for stabilizing lipid-nucleic acid formulations and provides MOF encapsulated lipid-nucleic acid formulations with improved stability.

Resumen de: WO2022241506A1

Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.

Resumen de: US2022370816A1

A method and system for noninvasively treating a neurodegenerative disorder, can involve determining characteristics indicative of physical attributes of a central nervous system, the characteristics including parameters for diminishing adverse impacts of a magnetothermal stimulation treatment for a neurodegenerative disorder with respect to the central nervous system, and applying as a part of the magnetothermal stimulation treatment and based on the characteristics of the physical attributes of the central nervous system, a magnetic field to the brain for a thermal stimulation of neuron cells within the brain.

Resumen de: US2022370644A1

Provided are targeted nanoparticles. In certain embodiments, the targeted nanoparticles comprise a nanoparticle and a myeloid cell (MC) targeting moiety stably associated with the outer surface of the nanoparticle. According to some embodiments, the MC targeting moiety is an immunosuppressive myeloid cell (isMC) targeting moiety. In certain embodiments, the targeted nanoparticles further comprise a detectable label (e.g., an in vivo imaging agent), a drug, or both. Also provided are compositions comprising the targeted nanoparticles of the present disclosure. Methods of using the targeted nanoparticles to image MCs (e.g., isMCs) and/or to modulate and/or disrupt MCs (e.g., isMCs) are also provided.

Resumen de: US2022370635A1

The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule.

Resumen de: US2022370636A1

Disclosed are methods for treating muscular diseases that involve the use of a nicotinamide adenine dinucleotide (NAD) activator.

Resumen de: US2022370488A1

Mucus penetrating nanoparticles for inducing, increasing, or enhancing an immune response typically include core of a blend of a biodegradable hydrophobic polymer and a hydrophilic polymer, wherein ≥50% of the biodegradable polymer is conjugated to the hydrophilic polymer, and the hydrophilic polymers forms a coating on the particle. The particles encapsulate a cargo, typically an antigen, adjuvant or other immunomodulator, or a nucleic acid encoding the antigen, or combination thereof. Pharmaceutical compositions including an effective amount of particles to induce an immune response in a subject in need thereof are also provided. Methods of inducing an immune response are also provided, and typically include administering to a subject, preferably via the respiratory tract, the pharmaceutical composition. In some embodiments, the subject has cancer or an infection of the lung.

Resumen de: US2022370354A1

This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.

Resumen de: US2022370616A1

Stabilized formulations of nucleic acids, including lipid nanoparticle formulations which encapsulate nucleic acids, are provided. Methods of making and of use of the formulations stabilized by chemical compounds are also provided.

Resumen de: US2022370611A1

Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

Resumen de: US2022372493A1

Disclosed herein are compositions and methods for targeted treatment of liver cancers with Paclitaxel and miR-122. The disclosed composition comprises RNA nanostructure conjugated to a hepatocyte targeting ligand, paclitaxel, and miR-122 for use in intracellular drug delivery to liver cancer cells. The RNA nanoparticle can involve three or more self-assembled synthetic RNA oligonucleotides that form a central core domain and at least three double-stranded arms arranged around the core domain and extending away from the central core domain.

Resumen de: US2022370370A1

Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles.

Resumen de: US2022370373A1

From diagnostic imaging to drug delivery, nanoparticles have found a tremendous variety of uses across fields. Often, when designing these nanoscale constructs, the two most important criteria are particle size and core loading. For example, small particles below 100 nm can have many advantages for drug delivery—including improved specificity to tumors through the enhanced permeability and retention (EPR) effect. Likewise, higher loading nanoparticles translate very well to more effective drug delivery and cancer imaging—allowing for lower dosage and reduced costs. Traditional formulations of nanoparticles using drug absorption or precipitation methods generally struggle to obtain >50% loading. Disclosed herein is a precipitation process allowing for production of stable particles at very high core loading by taking advantage of different time scales while maintaining biologically relevant sizes. New mixing designs allow for the separation of the precipitation and stabilization steps to generate these high loading nanoparticles.

Resumen de: US2022370363A1

A novel and innovative method of fabricating nanoparticles with reproducible characteristics from batch-to-batch and during scale-up. The method is a dipolymerization-precipitation reaction facilitated by the inverse electron demand Diels-Alder (IEDDA) reaction.

Resumen de: US2022370358A1

A process for producing a pharmaceutical formulation comprises the steps of:A) suspending a pharmaceutical active substance in an aqueous solution of a polymer;B) drying the mixture obtained in step A);wherein in step A) the pharmaceutical active substance is present in the form of particles having a d90 value in the particle size distribution of ≤1 μm and before step B) the pharmaceutical active substance is further contacted with an ionic surfactant.